Clinical Trial Update: XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study

View source ↗

Summary

A post-marketing, single-arm clinical study in India evaluating the XIENCE V Everolimus-eluting coronary stent system has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Restenosis

Drugs mentioned

• XIENCE V Everolimus Eluting Coronary Stent System (Everolimus-eluting coronary stent)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Coronary Disease, Coronary Artery Disease | Status: COMPLETED